A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) Article

Industry Collaboration International Collaboration

cited authors

  • Groen, H. J. M.; Socinski, M. A.; Grossi, F.; Juhasz, E.; Gridelli, C.; Baas, P.; Butts, C. A.; Chmielowska, E.; Usari, T.; Selaru, P.; Harmon, C.; Williams, J. A.; Gao, F.; Tye, L.; Chao, R. C.; Blumenschein, G. R.

authors

Publication Date

  • September 1, 2013

webpage

published in

category

keywords

  • combination therapy
  • efficacy
  • erlotinib
  • non-small-cell lung cancer
  • safety
  • sunitinib

start page

  • 2382

end page

  • 2389

volume

  • 24

issue

  • 9